Skip to search formSkip to main contentSkip to account menu

CDP870

Known as: CDP870s, 870s, CDP, 870, CDP 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

certolizumab pegol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
BACKGROUND Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) for… 
Review
2010
Review
2010
TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion
  • Y. WuB. Zhou
  • British Journal of Cancer
  • 2010
  • Corpus ID: 14944496
Tumour necrosis factor-alpha (TNF-α) is an important inflammatory factor that acts as a master switch in establishing an… 
Review
2010
Review
2010
TNF-α and its inhibitors in cancer
Tumor necrosis factor (TNF)-α is implicated in the same time in apoptosis and in cell proliferation. TNF-α not only acts as pro… 
Review
2009
Review
2009
Certolizumab pegol for the management of Crohn's disease in adults.
  • A. Rivkin
  • Clinical Therapeutics
  • 2009
  • Corpus ID: 26469956
Highly Cited
2007
Highly Cited
2007
Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti‐tumor necrosis factor &agr; agents
Background: Inhibitors of tumor necrosis factor &agr; (TNF&agr;) have demonstrated significant efficacy in chronic inflammatory… 
Review
2006
Review
2006
Drug Insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease
In the past decade, advances in the understanding of the pathogenesis of inflammatory bowel disease have permitted the… 
Highly Cited
2005
Highly Cited
2005
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
BACKGROUND & AIMS To investigate the efficacy and safety of certolizumab pegol (a polyethylene-glycolated Fab' fragment of anti… 
Highly Cited
2004
Highly Cited
2004
Pharmaceutical profiling in drug discovery for lead selection
Absorption Prediction.- Predicting Molecular Physical Properties.- In Silico Transporter Modeling and Its Application in Drug… 
Highly Cited
2004
Highly Cited
2004
Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate‐to‐severe Crohn's disease: an exploratory study
Background : CDP870 is a PEGylated Fab′ fragment of a humanized monoclonal antibody that neutralizes tumour necrosis factor‐α. 
Highly Cited
2002
Highly Cited
2002
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial.
OBJECTIVE Biological products that neutralize tumour necrosis factor alpha (TNF-alpha) are beneficial in rheumatoid arthritis (RA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)